Triple-Negative Breast Cancer Research: Why One Label Covers Different Tumors

A name made of absences

Most cancer names say what a tumor is. This one says what it is not.

Triple-negative means biomarker tests found three things missing. The cancer cells do not have estrogen receptors. They do not have progesterone receptors. And they make little or no HER2 protein.

Those three markers are the handles that most breast cancer drugs grab. NCI is direct about the consequence: therapies aimed at those biomarkers do not work here. That is why the disease can be harder to treat.

A label defined by absence groups together tumors that may differ from each other in ways the label cannot see.

What is known about who gets it

NCI reports several patterns. Triple-negative breast cancer is often diagnosed at a younger age. It is more common, and diagnosed younger, in Black women than in White women. It is more common in women with certain inherited gene changes, including BRCA1 or BRCA2.

The cause is unknown. Other risk factors are the same as for other breast cancers. The tumor is almost always invasive.

How the diagnosis is reached

There is no scan that shows triple-negative status. The finding comes from biomarker tests run on tissue from a biopsy.

Imaging still has a role. PET or CT scans show how far the cancer has spread. Stage is then assigned using extent of spread, triple-negative status, and other features such as tumor grade.

One label, several different settings

Treatment does not follow from the label alone. It follows from the setting, and NCI lists distinct approaches.

Before surgery. Chemotherapy may be given first to shrink the tumor. The immunotherapy drug pembrolizumab may be added. NCI notes that treatment before surgery may also improve long-term outcomes.

After surgery. More chemotherapy, more pembrolizumab, and radiation if cancer was found in or near lymph nodes or at the tumor margin. Olaparib is an option for people with a BRCA1 or BRCA2 mutation who received chemotherapy both before and after surgery.

Metastatic disease. Chemotherapy is usually first. Options include olaparib for BRCA1 or BRCA2 mutations, sacituzumab govitecan, and pembrolizumab. Radiation and surgery may be used to relieve symptoms.

So the same three negatives lead to different plans depending on stage, gene status, and what has already been tried.

The targets that do exist

Two of these drugs show that "no target" was never quite right.

Olaparib works off an inherited gene change, not the receptor status. That is a target the triple-negative label does not mention.

Sacituzumab govitecan is an antibody-drug conjugate. NCI describes it as an antibody linked to a toxic drug called SN-38, which enters the cancer cell and damages its DNA. It is approved for triple-negative breast cancer that has spread or cannot be removed by surgery, in people who have already had at least two systemic treatments, including one for metastatic disease.

That eligibility line matters. It is a later-line option, not a first choice.

Pembrolizumab brings immunotherapy into a disease once thought to have nothing to aim at.

What the label still does not tell you

• It does not say how fast a tumor will grow.
• It does not say whether chemotherapy will work.
• It does not sort people into research groups on its own.
• It does not carry a prognosis for any individual.

Ask about your own report

• What did my biomarker tests show, item by item?
• Have I been offered genetic counseling and BRCA testing?
• What is the plan before surgery, and what is it aiming at?
• Which options are first-line, and which come later?
• Is there a clinical trial that fits my situation?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.